Finerenone

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Finerenone and local guidelines before prescribing.

Mineralocorticoid antagonist

Mechanism

Non-steroidal mineralocorticoid receptor antagonist.

Uses

Chronic kidney disease with type 2 diabetes, heart failure with preserved EF.

Dosing

Side effects

Hyperkalaemia, hypotension, reduced eGFR, hyponatraemia.

Interactions

Strong CYP3A4 inhibitors contraindicated; potassium supplements.

Contraindications and cautions

Potassium above 5.0, Addison disease

Monitoring

Potassium, eGFR

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

Reduce start dose if eGFR 25–60

Overdose and reversal

Supportive

Special advice

Check potassium before starting and at 4 weeks.

More from the textbook: uses, cautions and other points
Where it is discussed in the book